Clinical trials: insulin glargine
Diabetes, Diabetes Mellitus, Type 2
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Africa, Asia, Europe, North America and South America. The purpose is to compare long-term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) in insulin naïve…
- Trial name
- DUAL™ VIII (NCT02501161)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 143 sites in United States, Argentina and 14 more
- Volunteers
- 1,012 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2
Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus
To compare the efficacy of prandial TI plus basal insulin versus prandial rapid acting, subcutaneous insulin plus basal insulin in subjects with type 2 diabetes who had an HbA1c >7.0% and <11.5%.
- Trial name
- NCT00539890
- Testing
- Technosphere Insulin
- Where
- 33 sites in Russia
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
This is a safety and efficacy study of ertugliflozin (MK-8835/PF-04971729) in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin and sitagliptin.
- Trial name
- NCT02036515
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Metformin
- Volunteers
- 464 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either insulin degludec (IDeg) or insulin glargine (IGlar).
- Trial name
- NCT01704417
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in HbA1c from baseline to endpoint (scheduled month 6) in adult participants with type 2 diabetes mellitus Secondary…
- Trial name
- EDITION I (NCT01499082)
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 807 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
The purpose of this pilot trial is to determine whether an intensive treatment with insulin glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients with recently diagnosed type 2 diabetes…
- Trial name
- NCT01181674
- Testing
- insulin glargine, metformin, acarbose
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- Population Health Research Institute
Type 2 Diabetes, Chronic Kidney Disease
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
- Trial name
- AWARD-7 (NCT01621178)
- Testing
- Dulaglutide, Insulin glargine, Insulin lispro
- Where
- 89 sites in United States, Brazil and 7 more
- Volunteers
- 577 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment
The purpose of this study is to compare insulin peglispro (LY2605541) to insulin glargine in Asian insulin naïve participants who have been treated with oral anti hyperglycemia medications.
- Trial name
- NCT01894568
- Testing
- Insulin Peglispro, Insulin Glargine, Oral Antihyperglycemic Medications (OAMs)
- Where
- 31 sites in Japan, South Korea and 1 more
- Volunteers
- 388 people
- Sponsor
- Eli Lilly and Company
Diabetes
A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety
This is a multicenter, randomized, open, parallel group, active-controlled study. The study period is 25 to 26 weeks, including screening period of 1-2 weeks and treatment period of 24 weeks.
- Trial name
- NCT02491528
- Testing
- insulin Aspart injection, insulin Aspart injection (NovoRapid)
- Where
- 2 sites in China
- Volunteers
- 563 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Type 2 Diabetes Mellitus
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT04957914
- Testing
- Insulin Glargine, LY3209590
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- Trial name
- NCT05699408
- Testing
- INS068 injection, Insulin Glargine
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus
A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use
A clinical study of the use of glargine insulin in 2 subjects with type two diabetes in China was carried out. The two kinds of injection methods were evaluated as subcutaneous injection of insulin glargine.
- Trial name
- NCT03420040
- Testing
- QS-M Needle Free Injector, Glargine pen
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Xijing Hospital
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit
The purpose of this study is to test whether a combination of two pills commonly used to treat outpatient diabetes called metformin and sitagliptin (januvia) could provide successful control of blood sugar levels in patients with…
- Trial name
- NCT02250794
- Testing
- metformin and sitagliptin, insulin glargine and insulin lispro
- Sponsor
- Rush University Medical Center
Diabetes Mellitus, Type 1
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
- Trial name
- NCT01600950
- Testing
- LY2963016, Lantus
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents with type 1 diabetes.
- Trial name
- NCT01497574
- Testing
- insulin detemir, insulin glargine
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood…
- Trial name
- EFFICACY (NCT00909480)
- Testing
- insulin detemir, insulin glargine
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 457 people
- Sponsor
- Novo Nordisk A/S
To Assess the Glycemic Control of Insulin Glargine in Combination With Regular Insulin in Type 1 Diabetes in Children
Comparison of Insulin Glargine and Regular Insulin Versus NPH and Regular Insulin in the Treatment of T1DM
To compare the glycemic control in children with type 1 diabetes using insulin Glargine and regular insulin as basal bolus therapy versus Neutral Protamine Hagedorn insulin (NPH) and regular insulin.
- Trial name
- NCT05709938
- Testing
- Glargine and regular insulin versus NPH and regular insulin
- Where
- Pakistan
- Volunteers
- 68 people
- Sponsor
- King Edward Medical University
Diabetes Mellitus Type II
20 Week Bridging Study in Type II DM
A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT00563225
- Testing
- Insulin Glargine
- Volunteers
- 90 people
- Sponsor
- Sanofi